Victor Aboyans
French Institute of Health and Medical Research
EpidemiologyInternal medicineSurgeryDemographyCardiologyIntensive care medicineProspective cohort studyCoronary artery diseaseAnkleDiseaseStenosisPopulationIn patientArterial diseaseMyocardial infarctionStrokeDiabetes mellitusMedicineBlood pressure
478Publications
80H-index
84.8kCitations
Publications 420
Newest
Source
#1Frank L.J. VisserenH-Index: 65
#2François MachH-Index: 79
Last. Davide CapodannoH-Index: 74
view all 106 authors...
3 CitationsSource
#1Michael H. CriquiH-Index: 152
#2Kunihiro MatsushitaH-Index: 29
Last. Francisco UjuetaH-Index: 4
view all 10 authors...
Lower extremity peripheral artery disease (PAD) affects >230 million adults worldwide and is associated with increased risk of various adverse clinical outcomes (other cardiovascular diseases such as coronary heart disease and stroke and leg outcomes such as amputation). Despite its prevalence and clinical importance, PAD has been historically underappreciated by health care professionals and patients. This underappreciation seems multifactorial (eg, limited availability of the first-line diagno...
1 CitationsSource
Source
Abstract null null Background null Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk. null null null Objectives null In a post hoc analysis of the ODYSSEY Outcomes (Evaluation of Cardiovasc...
2 CitationsSource
#1François-Xavier Lapébie (Paul Sabatier University)
#2Victor Aboyans (University of Limoges)H-Index: 80
Last. Alessandra Bura-Rivière (Paul Sabatier University)H-Index: 15
view all 9 authors...
OBJECTIVE The aim of this study was to examine the external applicability of the COMPASS and the VOYAGER-PAD trials in patients with lower extremity artery disease (LEAD) in the real world. METHODS This was a multicentre retrospective analysis of prospectively collected COPART data, a French multicentre registry of patients hospitalised for symptomatic LEAD. The proportion of patients eligible for the combination of rivaroxaban 2.5 mg twice daily plus aspirin based on either COMPASS or VOYAGER-P...
Source
#1Lucia Mazzolai (UNIL: University of Lausanne)H-Index: 33
#2Adriano Alatri (UNIL: University of Lausanne)H-Index: 13
view all 12 authors...
Although COVID-19 seems to be the leading topic in researcha number of outstanding studies have been published in the field of aorta and peripheral vascular diseases likely affecting our clinical practice in the near future. This review article highlights key research on vascular diseases published in 2020. Some studies have shed light in the pathophysiology of aortic aneurysm and dissection suggesting a potential role for kinase inhibitors as new therapeutic options. A first proteogenomic study...
1 CitationsSource
#1Victor Aboyans (University of Limoges)H-Index: 80
#2Rupert Bauersachs (University of Mainz)H-Index: 34
Last. Basil S. Lewis (Technion – Israel Institute of Technology)H-Index: 106
view all 16 authors...
The aim of this collaborative document is to provide an update for clinicians on best antithrombotic strategies in patients with aortic and/or peripheral arterial diseases. Antithrombotic therapy is a pillar of optimal medical treatment for these patients at very high cardiovascular risk. While the number of trials on antithrombotic therapies in patients with aortic or peripheral arterial diseases is substantially smaller than for those with coronary artery disease, recent evidence deserves to b...
1 CitationsSource
Source
#1Lucia Mazzolai (UNIL: University of Lausanne)H-Index: 33
#2Walter Ageno (University of Insubria)H-Index: 70
Last. Saskia Middeldorp (UvA: University of Amsterdam)H-Index: 56
view all 13 authors...
This consensus document is proposed to clinicians to provide the whole spectrum of deep vein thrombosis management as an update to the 2017 consensus document. New data guiding clinicians in indicating extended anticoagulation, management of patients with cancer, and prevention and management of post-thrombotic syndrome are presented. More data on benefit and safety of non-vitamin K antagonists oral anticoagulants are highlighted, along with the arrival of new antidotes for severe bleeding manag...
2 CitationsSource